News

Despite nearly doubling revenues to $21+ billion in the past 5 years, BSX has dropped 60% in the past year

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the company's bruised financials.

Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q2 CY2026, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.

Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls

After a week of wild swings that rattled portfolios and left investors guessing, Wall Street analysts are already reshuffling their ratings on Friday morning, with some surprising cuts and upgrades across sectors from utilities to gaming that could reshape how you think about your positions.

Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.

Boston Scientific underperformed the broader market, though analysts remain optimistic, citing strong earnings execution, innovation, and meaningful upside from current levels.

Analyst fair value for Boston Scientific has shifted from US$75.00 to US$72.25, pointing to a modest reset in price targets. This change lines up with recent research that lowers expectations for Watchman and electrophysiology while still recognizing strengths across the broader portfolio and generally positive ratings. As you read on, you will see how these moving targets, both bullish and bearish, shape the evolving Boston Scientific story and what to watch next. Stay updated as the Fair...

Moby summary of Boston Scientific Corporation's Q2 2026 earnings call

Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.3% and

Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.

Healthcare stocks were slightly lower Wednesday afternoon, with the NYSE Healthcare Index down 0.1%

Boston's tempered 2026 outlook is likely due in part to its recently announced plans to initiate a global restructuring programme.

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41

Boston Scientific (BSX) delivered earnings and revenue surprises of +3.61% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The main US stock measures were mostly trending higher in Wednesday's premarket activity as traders

July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.

Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.

The plan involves transferring production lines and cutting jobs, following a slowdown in two of the company’s key product lines.

Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.

J&J's MedTech growth slowed down in Q2 as Cardiovascular lagged, but new product launches and stronger Vision, Surgery and Orthopedics may lift H2 sales.

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

Device makers with cash flow yields of 5% to 6% now trade at a 20% to 30% discount to the S&P 500 index.

Boston Scientific (NYSE:BSX) has enrolled the first patients in the global FARADIGM trial. The study evaluates the Faraflex pulsed field ablation device for the treatment of atrial fibrillation. This milestone marks the formal start of large scale clinical testing for the Faraflex system. Boston Scientific is a major player in cardiac rhythm and electrophysiology devices, and the FARADIGM trial adds another clinical program to that portfolio. Atrial fibrillation treatments have been an area...

Boston Scientific (BSX) reached $43.19 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.

The market is offering a steep discount on this medical device maker, but the price tag comes with a story about slowing growth. Here’s how to read it.